Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Big Health
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Feb 2026: Big Health raised $23.7m in strategic funding co-led by .406 Ventures and AlleyCorp. No adverse media involving Big Health found in HSH's search of the last 24 months.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Big Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Digital therapeutics (SleepioRx, DaylightRx) are FDA-cleared; no recalls, safety notices or warning letters involving Big Health found in HSH's search of the last 24 months.
Contract performance
May 2025: trade press reported Sleepio still lacked NHS England national funding despite 2022 NICE guidance, limiting access in England (Scotland offers it). Feb 2026: company cited Henry Ford and Northwell as US delivery partners.
Competitors
No competitors linked yet.